Individualized chemotherapy in advanced nsclc patients based on mRNA levels of BRCA1 and RRM1

Chinese Journal of Cancer Research

Volumn 24, Issue 3, 2012, Pages 226-231

  Ren, Sheng Xiang ^a   Li, Ai Wu ^a   Zhou, Song Wen ^a   Zhang, Ling ^a   Wang, Yong Sheng ^a   Li, Bing ^a   Chen, Xiao Xia ^a   Zhang, Jie ^a   Xu, Jian Fang ^a   Zhou, Cai Cun ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

BRCA1; Individualized chemotherapy; Non small cell lung cancer; RRM1

Indexed keywords

BETA ACTIN; BRCA1 PROTEIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; RIBONUCLEOTIDE REDUCTASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ASSESSMENT; DISEASE SEVERITY; DRUG EFFECT; DRUG MEGADOSE; DYSPNEA; FATIGUE; FEMALE; HEMOPTYSIS; HUMAN; HYPERSENSITIVITY REACTION; LOW DRUG DOSE; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; RNA ISOLATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84865174769     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.1007/s11670-012-0226-4     Document Type: Article

References (23)

1. Chen WQ, Zhang SW, Zou XN, et al. Cancer incidence and mortality in China, 2006. Chin J Cancer Res 2011; 23:3-9.
2. Camps C, Sirera R, Iranzo V, et al. Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy. Clin Lung Cancer 2007; 8:369-75. (Pubitemid 46924057)
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-8. (Pubitemid 34438899)
4. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543-51.
5. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007; 99:847-57.
6. Ota S, Ishii G, Goto K, et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-smallcell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 2009; 64:98-104.
7. Kim YH, Ishii G, Goto K, et al. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with smallcell lung cancer. Lung Cancer 2009; 65:105-11.
8. Su C, Zhou S, Zhang L, et al. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med Oncol 2011 28:1411-7.
9. Ren S, Zhou S, Zhang L, et al. High-level mRNA of excision repair cross complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients. Cancer Invest 2010; 28:1078-83.
10. Guo QZ, Wang J, Bai H, et al. High expression of ERCC1 is a poor prognostic factor in Chinese patients with non-small cell lung cancer receiving cisplatin-based therapy. Chin J Cancer Res 2010; 22:296-302.
11. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007; 25:2747-54. (Pubitemid 47123183)
12. Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lungcancer. J Clin Oncol 2007; 25:2741-6. (Pubitemid 47123182)
13. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356:800-8. (Pubitemid 46294612)
14. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatintreated advanced non-small cell lung cancer patients. Clin Cancer Res 2004; 10:1318-25. (Pubitemid 38365223)
15. Boukovinas I, Papadaki C, Mendez P, et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One 2008; 3:e3695.
16. Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One 2007; 2:e1129.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer lnst 2000; 92:205-16. (Pubitemid 30099779)
18. Azuma K, Sasada T, Kawahara A, et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 2009; 64:326-33.
19. Takenaka T, Yoshino I, Kouso H, et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer 2007; 121:895-900. (Pubitemid 47106222)
20. de las Peñas R, Sanchez-Ronco M, Alberola V, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006; 17:668-75.
21. Vilmar A, Sorensen JB. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer 2009; 64:131-9.
22. Reguart N, Cardona AF, Carrasco E, et al. BRCA1: a new genomic marker for non-small-cell lung cancer. Clin Lung Cancer 2008; 9:331-9.
23. Luo J, Leaw SJ, Xu Y, et al. Comparison of cisplatin- and carboplatinbased third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer. Med Oncol 2011; 28:1418-24.